Gene therapy for rheumatoid arthritis

Adam L Reinhardt, Raphael Hirsch

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Therapy for rheumatoid arthritis (RA) has seen significant advances over the Past decade. The use of biologic agents, such as TNF-α inhibitors, have led to improvement in up to 60% of RA patients. Unfortunately, biologic therapy also presents significant limitations, including systematic side effects, a short half-life with requirement for frequent dosing, and a lack of curative response. Owing to such limitations, the ideal therapy for RA remains unrealized. Progress in the field of gone therapy provides interesting and applicable methods to overcome many of these deficits. In this review we will discuss some of these advances, focusing on the development of new vectors, gene-therapy targets and regulatory mechanisms. With continued efforts in this field, the hope for a lasting, regulated and possibly curative modality appears attainable.

Original languageEnglish (US)
Pages (from-to)403-413
Number of pages11
JournalFuture Rheumatology
Volume2
Issue number4
DOIs
StatePublished - Aug 1 2007

Fingerprint

Genetic Therapy
Rheumatoid Arthritis
Biological Therapy
Biological Factors
Half-Life
Therapeutics

Keywords

  • Adeno-associated virus
  • Adenovirus
  • Gene therapy
  • Inflammation
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Gene therapy for rheumatoid arthritis. / Reinhardt, Adam L; Hirsch, Raphael.

In: Future Rheumatology, Vol. 2, No. 4, 01.08.2007, p. 403-413.

Research output: Contribution to journalReview article

Reinhardt, Adam L ; Hirsch, Raphael. / Gene therapy for rheumatoid arthritis. In: Future Rheumatology. 2007 ; Vol. 2, No. 4. pp. 403-413.
@article{7111489c9fd84565adf88cad28301c51,
title = "Gene therapy for rheumatoid arthritis",
abstract = "Therapy for rheumatoid arthritis (RA) has seen significant advances over the Past decade. The use of biologic agents, such as TNF-α inhibitors, have led to improvement in up to 60{\%} of RA patients. Unfortunately, biologic therapy also presents significant limitations, including systematic side effects, a short half-life with requirement for frequent dosing, and a lack of curative response. Owing to such limitations, the ideal therapy for RA remains unrealized. Progress in the field of gone therapy provides interesting and applicable methods to overcome many of these deficits. In this review we will discuss some of these advances, focusing on the development of new vectors, gene-therapy targets and regulatory mechanisms. With continued efforts in this field, the hope for a lasting, regulated and possibly curative modality appears attainable.",
keywords = "Adeno-associated virus, Adenovirus, Gene therapy, Inflammation, Rheumatoid arthritis",
author = "Reinhardt, {Adam L} and Raphael Hirsch",
year = "2007",
month = "8",
day = "1",
doi = "10.2217/17460816.2.4.403",
language = "English (US)",
volume = "2",
pages = "403--413",
journal = "Future Rheumatology",
issn = "1746-0816",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Gene therapy for rheumatoid arthritis

AU - Reinhardt, Adam L

AU - Hirsch, Raphael

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Therapy for rheumatoid arthritis (RA) has seen significant advances over the Past decade. The use of biologic agents, such as TNF-α inhibitors, have led to improvement in up to 60% of RA patients. Unfortunately, biologic therapy also presents significant limitations, including systematic side effects, a short half-life with requirement for frequent dosing, and a lack of curative response. Owing to such limitations, the ideal therapy for RA remains unrealized. Progress in the field of gone therapy provides interesting and applicable methods to overcome many of these deficits. In this review we will discuss some of these advances, focusing on the development of new vectors, gene-therapy targets and regulatory mechanisms. With continued efforts in this field, the hope for a lasting, regulated and possibly curative modality appears attainable.

AB - Therapy for rheumatoid arthritis (RA) has seen significant advances over the Past decade. The use of biologic agents, such as TNF-α inhibitors, have led to improvement in up to 60% of RA patients. Unfortunately, biologic therapy also presents significant limitations, including systematic side effects, a short half-life with requirement for frequent dosing, and a lack of curative response. Owing to such limitations, the ideal therapy for RA remains unrealized. Progress in the field of gone therapy provides interesting and applicable methods to overcome many of these deficits. In this review we will discuss some of these advances, focusing on the development of new vectors, gene-therapy targets and regulatory mechanisms. With continued efforts in this field, the hope for a lasting, regulated and possibly curative modality appears attainable.

KW - Adeno-associated virus

KW - Adenovirus

KW - Gene therapy

KW - Inflammation

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=34547855869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547855869&partnerID=8YFLogxK

U2 - 10.2217/17460816.2.4.403

DO - 10.2217/17460816.2.4.403

M3 - Review article

VL - 2

SP - 403

EP - 413

JO - Future Rheumatology

JF - Future Rheumatology

SN - 1746-0816

IS - 4

ER -